Application of FGF21 / GLP-1 fusion protein

By using the FGF21/GLP-1 fusion protein to prepare drugs, the problem of existing treatments being unable to effectively control blood sugar and side effects has been solved, achieving effective treatment and functional improvement for diseases such as type 2 diabetes.

CN122140897APending Publication Date: 2026-06-05SUNSHINE LAKE PHARMA CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202511813536.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-12-04
Filing Date
2025-12-03
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

Existing treatments for type 2 diabetes, obesity, fatty liver disease, steatohepatitis, and dyslipidemia cannot completely control blood sugar levels and may be accompanied by side effects. The efficacy and safety of fusion proteins are affected by a variety of factors.

Method used

An FGF21/GLP-1 fusion protein is provided for the preparation of drugs that, by administering pharmaceutically acceptable doses to individuals in need, reduce indicators such as HbA1c, blood glucose, body weight, and liver fat content, or improve adiponectin, insulin sensitivity, and β-cell function.

Benefits of technology

It effectively treats type 2 diabetes, obesity, fatty liver disease, steatohepatitis, and dyslipidemia, reduces related indicators, improves related functions, and maximizes treatment effectiveness while minimizing risks.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of FGF21 / GLP-1 fusion protein in preparation of a medicine. The medicine is used for preventing and / or treating at least one of type 2 diabetes mellitus, obesity, steatohepatitis and triglyceride. The FGF21 / GLP-1 fusion protein can effectively treat at least one of type 2 diabetes mellitus, obesity, steatohepatitis and triglyceridemia, and especially can reduce at least one of HbA1c, blood sugar, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol and low-density lipoprotein cholesterol of an applicant. Or at least one of adiponectin, insulin sensitivity, and beta cell function of the user is improved.
Need to check novelty before this filing date? Find Prior Art